SCHEMBL21179078

SCHEMBL21179078

C[C@H]1O[C@@H](n2cc(F)c(=O)n(COCc3ccccc3)c2=O)[C@H](OCOCc2ccccc2)[C@@H]1O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.34
TSHR P16473 1/20 0.34
MAPT P10636 1/20 0.34
PMP22 Q01453 1/20 0.34
HBB P68871 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
P2RY6 Q15077 2/20 0.32
P2RY14 Q15391 2/20 0.32
TP53 P04637 2/20 0.32
MDM2 Q00987 2/20 0.32
NT5E P21589 1/20 0.32
NAAA Q02083 1/20 0.31
MDM4 O15151 1/20 0.30
HSP90AA1 P07900 1/20 0.30
HSP90AB1 P08238 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21190350 0.93 LMNA (0.34) LMNATSHRMAPTPMP22HBB
SCHEMBL21179153 0.89 LMNA (0.45) LMNATSHRMAPTPMP22HBB
SCHEMBL21179248 0.85 LMNA (0.38) LMNATSHRMAPTPMP22HBB
SCHEMBL22824012 0.77 LMNA (0.38) LMNATSHRMAPTPMP22HBB
SCHEMBL21178986 0.77 LMNA (0.38) LMNATSHRMAPTPMP22HBB
SCHEMBL21190333 0.74 HPGD (0.39) LMNAMEN1KMT2AALDH1A1CYP2C9
SCHEMBL21178995 0.73 HPGD (0.33) MEN1KMT2AALDH1A1CYP2C9CYP2C19
SCHEMBL15034195 0.71 P2RY6 (0.36) ALDH1A1P2RY6NT5E
SCHEMBL14900680 0.70 ALDH1A1 (0.33) MEN1KMT2AALDH1A1
SCHEMBL19418520 0.70 ALDH1A1 (0.32) ALDH1A1P2RY6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11427550-B2 5-fluorouracil compounds NUCORION PHARMACEUTICALS, INC. (US) 2022-08-30 US disclosed
US-20200399227-A1 5-FLUOROURACIL COMPOUNDS NUCORION PHARMACEUTICALS, INC. 2020-12-24 US disclosed
US-20200399227-A1 5-FLUOROURACIL COMPOUNDS NUCORION PHARMACEUTICALS, INC. 2020-12-24 US disclosed
WO-2019143860-A1 5-FLUOROURACIL COMPOUNDS NUCORION PHARMACEUTICALS, INC. (US) 2019-07-25 WO disclosed
WO-2019143860-A1 5-FLUOROURACIL COMPOUNDS NUCORION PHARMACEUTICALS, INC. (US) 2019-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399227-A1 5-FLUOROURACIL COMPOUNDS DPYD, DHFR, FAU LMNA 1225/4885TSHR 3089/4885MAPT 3566/4885
US-11427550-B2 5-fluorouracil compounds DPYD, DHFR, MTHFD1 LMNA 1038/4885TSHR 3292/4885MAPT 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.